<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Mol. Cancer</journal-id><journal-title-group><journal-title>Molecular Cancer</journal-title></journal-title-group><issn pub-type="epub">1476-4598</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4995750</article-id><article-id pub-id-type="publisher-id">539</article-id><article-id pub-id-type="doi">10.1186/s12943-016-0539-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Li</surname><given-names>Yaqi</given-names></name><address><email>yaqilifudan@sohu.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Liang</surname><given-names>Lei</given-names></name><address><email>llknight115@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Dai</surname><given-names>Weixing</given-names></name><address><email>daiweixing2015@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Cai</surname><given-names>Guoxiang</given-names></name><address><email>gxcai2015@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Ye</given-names></name><address><email>yexufuscc@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Xinxiang</given-names></name><address><email>dr_xxli@sina.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Li</surname><given-names>Qingguo</given-names></name><address><phone>86-18918298120</phone><email>oncosurgeonli@sohu.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Cai</surname><given-names>Sanjun</given-names></name><address><phone>86-13901815189</phone><email>caisanjun_sh@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, 270 Dong&#x02019;an Road, Shanghai, 20032 China </aff><aff id="Aff2"><label>2</label>Department of Oncology, Shanghai Medical College, Fudan University, 270 Dong&#x02019;an Road, Shanghai, 20032 China </aff></contrib-group><pub-date pub-type="epub"><day>24</day><month>8</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>8</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>15</volume><issue>1</issue><elocation-id>55</elocation-id><history><date date-type="received"><day>31</day><month>5</month><year>2016</year></date><date date-type="accepted"><day>15</day><month>8</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Colorectal cancer (CRC) is 3rd most commonly diagnosed cancer in males and the second in females. PD-1/PD-L1 axis, as an immune checkpoint, is up-regulated in many tumors and their microenvironment. However, the prognostic value of PD-1/PD-L1 in CRC remains unclear.</p></sec><sec><title>Methods</title><p>The Cancer Genome Atlas (TCGA) database (<italic>N</italic>&#x02009;=&#x02009;356) and Fudan University Shanghai Cancer Center (FUSCC) cohort of patients (<italic>N</italic>&#x02009;=&#x02009;276) were adopted to analyze the prognostic value of PD-L1 in colorectal tumor cells (TCs) and of PD-1 in tumor infiltrating cells (TILs) for CRC. Subgroup analyses were conducted&#x000a0;in FUSCC cohort according to patients&#x02019; status of mismatch repair.</p></sec><sec><title>Results</title><p>In TCGA cohort, the cut-off values of PD-1 and PD-L1 expression were determined by X-tile program, which were 4.40 and 2.92, respectively. Kaplan-Meier analysis indicated that higher PD-1 and PD-L1 expressions correlated with better OS (<italic>P</italic>&#x02009;=&#x02009;0.032 and <italic>P</italic>&#x02009;=&#x02009;0.002, respectively). In FUSCC cohort, expressions of PD-1 on TILs and PD-L1 on TCs were analyzed separately by immunohistochemistry (IHC) staining based on a TMA sample (<italic>N</italic>&#x02009;=&#x02009;276) and revealed that both TILs-PD-1 and TCs-PD-L1 were associated with OS (<italic>P</italic>&#x02009;=&#x02009;0.006 and <italic>P</italic>&#x02009;=&#x02009;0.002, respectively) and DFS (<italic>P</italic>&#x02009;=&#x02009;0.025 and <italic>P</italic>&#x02009;=&#x02009;0.004, respectively) of CRC patients. Multivariate Cox regression analysis indicated TILs-PD-1 was an independent prognostic factor both for OS and DFS of CRC patients (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). Subgroup analyses showed that TILs-PD-1 was an independent prognostic factor for both OS and DFS in CRC patients in MSS-proficient subgroup (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05), while neither of them correlated with OS or DFS in MSS-deficient subgroup (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05).</p></sec><sec><title>Conclusions</title><p>Higher expressions of PD-1 and PD-L1 correlates with better prognosis of CRC patients. TILs-PD-1 is an independent prognostic factor for OS and DFS of CRC patients, especially for MMR-proficient subgroup.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s12943-016-0539-x) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>PD-1</kwd><kwd>PD-L1</kwd><kwd>Tumor infiltrating lymphocytes</kwd><kwd>Colorectal cancer</kwd><kwd>The cancer genome atlas</kwd><kwd>Prognosis</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>81372646</award-id><award-id>81101586</award-id><principal-award-recipient><name><surname>Cai</surname><given-names>Sanjun</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution>National Key Basic Research Program of China</institution></funding-source><award-id>2014CBA02002</award-id><principal-award-recipient><name><surname>Cai</surname><given-names>Sanjun</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Colorectal cancer (CRC) is the third most commonly diagnosed cancer in males and the second in females, accounting for approximately 9.7&#x000a0;% of total cancer cases and approximately 8.5&#x000a0;% of cancer deaths [<xref ref-type="bibr" rid="CR1">1</xref>]. A considerable proportion of CRC patients develop local recurrence and distant metastasis within 5&#x000a0;years after surgical treatment. Immunotherapy has reached center stage in the field of second-line therapy in oncology treatment, and anti-PD-1 therapy has shown objective responses in variety of human malignancies, including melanoma, non-small cell lung cancer and renal cell carcinoma [<xref ref-type="bibr" rid="CR2">2</xref>]. However, only microsatellite instable (MSI) subset of CRC seems to be a good candidate for checkpoint blockage immunotherapy [<xref ref-type="bibr" rid="CR3">3</xref>] and the mechanisms are still controversial.</p><p>Tumor-infiltrating lymphocytes (TILs) are widely considered as reflection of primary host immune response against solid tumors. Evidence has shown that tumor infiltration by activated CD8<sup>+</sup> cytotoxic T lymphocytes correlates with better survival of CRC patients [<xref ref-type="bibr" rid="CR4">4</xref>]. PD-1/PD-L1 axis, as an immune checkpoint, is up-regulated in many tumors and their microenvironment, and is a negative feedback system that represses Th1 cytotoxic immune responses [<xref ref-type="bibr" rid="CR5">5</xref>]. The engagement of PD-1 by its ligands (PD-L1 and PD-L2) induces down-regulation of antigen-stimulated lymphocyte proliferation and cytokine (such as IFN-&#x003b3; and IL-2) production, resulting in lymphocyte deletion and in the induction of immunological tolerance [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>]. Compared to PD-L2, which can be detected only in activated dendritic cells (DC) and macrophages, PD-L1 is constitutively expressed by T and B cells, DC and macrophages [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>], and it is also expressed in additional cell types, such as endothelial, pancreatic and muscle cells [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p>The expression of PD-L1 in tumor cells (TCs) has been validated as a predictive marker for tumor response to anti-PD-1 or PD-L1 immunotherapy in different malignancies [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. However, the prognostic value of PD-1 and PD-L1 expression in different cancers are still controversial. In the present study, we used 356 cases in The Cancer Genome Atlas (TCGA) database and a tissue microarray (TMA) including 276 well-documented, clinically annotated CRC specimens in Fudan University Shanghai Cancer Center (FUSCC) to investigate the expression of PD-1 and PD-L1 in CRC and their clinical significance.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>The cancer genome atlas (TCGA) database</title><p>PD-1 and PD-L1 expression in patients of CRC and clinical data of TCGA database are available from the website of Cancer Genomics Browser of University of California Santa Cruz (<ext-link ext-link-type="uri" xlink:href="https://genome-cancer.ucsc.edu/">https://genome-cancer.ucsc.edu/</ext-link>). In total, 356 primary CRC tumors from patients with detailed PD-1 and PD-L1 expression data were chosen from the updated TCGA database according to parameters defined in a previous study [<xref ref-type="bibr" rid="CR13">13</xref>]. Only patients with fully characterized tumors, intact overall survival (OS), complete RNAseq information, and patients without pretreatment were included. Clinicopathological characteristics, including age, gender, tumor location, historical type, TNM stage, venous invasion, extent of TILs, microsatellite (MS) status, pretreatment CEA and overall survival were collected.</p></sec><sec id="Sec4"><title>Tissue microarray (TMA) construction and clinicopathological features</title><p>The TMA used for this study includes 276 unselected, non-consecutive, primary, and sporadic CRCs treated between January 2007 and November 2009 in Fudan University Shanghai Cancer Center (FUSCC). Construction of this TMA has been previously described in detail [<xref ref-type="bibr" rid="CR14">14</xref>]. Briefly, formalin-fixed, paraffin-embedded tissue blocks from resected CRC were obtained. Tissue cylinders with a 0.6&#x000a0;mm diameter were punched from representative tissue areas of each donor tissue block and brought into one recipient paraffin block (30&#x02009;&#x000d7;&#x02009;25&#x000a0;mm). Each TMA spot included at least 50&#x000a0;% tumor cells. The histological types were confirmed by experienced pathologists.</p><p>Patients&#x02019; demographic and clinicopathological variables, including age, sex, primary site, histological type, TNM stage, pathological grade, venous/nervous invasion, regional lymph node retrieval, MMS status, pretreatment CEA level, treatment type et al., were retrieved from the FUSCC database. All patients were restaged according to the 7th edition of the TNM-UICC/AJCC classification. Venous/nervous invasion was identified by experienced pathologists using hemotoxylin/eosin (HE) staining. The regimens used varied because of long duration of data collection. So, we simply classify patients into two groups according to whether patients had received adjuvant chemotherapy or not. Patients were followed up regularly according to NCCN guidelines. Physical examination and serum tumor biomarkers, including CEA, were performed every 3 to 6&#x000a0;months for the first 2&#x000a0;years, 6&#x000a0;months within the third to fifth year, then annually. Chest/abdominal/pelvis CTs were performed annually for up to 5&#x000a0;years, and colonoscopy was performed 1st year after treatment and repeated in 3rd year if no advanced adenoma was found and then every 5&#x000a0;years. As this study described the prognosis of patients with CRC, analysis of OS and DFS were ascertained. The OS was defined as the time from treatment to death from any cause, and the DFS was defined as the time from treatment to the first recurrence or death. The survival data was provided by Clinical Statistics Center of FUSCC, relying on the hospital medical records follow-up platform or contacts with patients by phone or email. Patients who were alive at last follow-up were censored for analysis.</p></sec><sec id="Sec5"><title>Immunohistochemistry (IHC)</title><p>Immunohistochemical (IHC) staining was performed according to standard protocol. Briefly, paraffin-embedded samples were cut into 4&#x000a0;&#x003bc;m sections and placed on polylysine-coated slides. Paraffin sections were baked overnight at 58&#x000a0;&#x000b0;C, de-paraffinized in xylene, rehydrated through graded ethanol, quenched for endogenous peroxidase activity in 0.3&#x000a0;% hydrogen peroxide at 37&#x000a0;&#x000b0;C for 15&#x000a0;min, and processed for antigen retrieval by high pressure cooking in citrate antigen retrieval solution (pH&#x02009;=&#x02009;6.0) for about 10&#x000a0;min for PD-L1 and EDTA antigen retrieval solution (pH&#x02009;=&#x02009;8.0) for about 4&#x000a0;min for PD-1. Sections were incubated at 37&#x000a0;&#x000b0;C for 1.5&#x000a0;h with rabbit monoclonal antibodies against PD-1 (1:100, ab137132, Abcam, Cambridge, MA, USA) and PD-L1 (1:50, ab174838, Abcam, Cambridge, MA, USA) in a moist chamber. Immunostaining was performed using the EnVision<sup>+</sup>System-HRP (AEC) (K4005, Dako, Glostrup, Denmark), which resulted in a brown-colored precipitate at the antigen site. Subsequently, sections were counterstained with hematoxylin (Sigma-Aldrich, St Louis, MO, USA) and mounted in a non-aqueous mounting medium. All runs included a no primary antibody control.</p></sec><sec id="Sec6"><title>Evaluation of PD-1 and PD-L1 expression TCs and TILs in FUSCC cohort</title><p>The immunohistochemically stained tissue sections were scored separately by two pathologists blinded to the clinicopathological parameters. The staining intensity was scored as 0 (negative), 1 (weak), 2 (medium) or 3 (strong). Extent of staining was scored as 0 (&#x0003c;5&#x000a0;%), 1(5&#x02013;25&#x000a0;%), 2 (26&#x02013;50&#x000a0;%), 3 (51&#x02013;75&#x000a0;%) and 4 (&#x0003e;75&#x000a0;%) according to the percentages of the positive staining areas in relation to the whole carcinoma area. Scores for staining intensity and percentage positivity of cells were then multiplied to generate the immunoreactivity score (IRS) for each case. Samples having a final staining score of&#x02009;&#x02264;&#x02009;4 were considered to be low and those with score of&#x02009;&#x0003e;&#x02009;4 were considered to be high.</p><p>The extent of TILs was assessed in HE stained TMA preparations using a 4-degree scale on the visual estimation and recorded as 0 (absent), 1 (&#x0003c;30&#x000a0;%), 2 (30&#x000a0;%&#x02013;60&#x000a0;%) and 3 (&#x0003e;60&#x000a0;%). Samples with a score of 0 or 1 were considered negative and those with a score of 2 or 3 were considered positive. The expression of PD-1 in TILs by IHC method&#x000a0;was evaluated using IRS mentioned above.</p></sec><sec id="Sec7"><title>Microsatellite (MS) status and mismatch repair (MMR) status</title><p>In the TCGA cohort, MSI was evaluated by exome sequence analysis [<xref ref-type="bibr" rid="CR15">15</xref>]. Based on the assay, 243 CRCs in the TCGA cohort could be classified as MSS and 113 as MSI. In the FUSCC cohort, CRCs were stratified according to DNA mismatch repair (MMR) status as described elsewhere [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Briefly, MMR-proficient tumors were defined as those simultaneously expressing MutL homolog 1 (MLH1), MutS homolog 2 (MSH2) and MutS homolog 6 (MSH6), while MMR-deficient tumors were defined as those lacking expression of at least one of these markers. Based on these features, 176 CRCs in FUSCC cohort could be classified as MMR-proficient and 100 as MMR-deficient.</p></sec><sec id="Sec8"><title>Statistical analysis</title><p>Statistical evaluation was conducted with SPSS 22.0 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism v.6 (La Jolla, CA, USA). X-tile 3.6.1 software [<xref ref-type="bibr" rid="CR18">18</xref>] (Yale University, New Haven, CT, USA) was used to determine the optimal cut-off values for PD-1 and PD-L1 expression in TCGA cohort. Chi-square test was used to analyze the relationship between clinicopathological parameters and PD-l, PD-L1 expressions. Survival analysis was performed using the Kaplan-Meier method and Cox regression model. <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 was considered statistically significant. All confidence intervals (CIs) were stated at the 95&#x000a0;% confidence level.</p></sec></sec><sec id="Sec9"><title>Results</title><sec id="Sec10"><title>Clinical characteristics of patients with CRC in TCGA cohort and FUSCC cohort</title><p>In the TCGA cohort, the median age of all 356 CRC patients was 66, ranging from 31 to 90&#x000a0;years old. 199 (55.9&#x000a0;%) were male patients and 157 (44.1&#x000a0;%) were female patients. The median follow-up time was 13.4&#x000a0;months and 68 patients died during follow-up. In the FUSCC cohort, the median age of 276 CRC patients was 57, ranging from 27 to 85&#x000a0;years old. 166 (60.1&#x000a0;%) were male and 110 (39.9&#x000a0;%) were female. The median follow-up time was 61.0&#x000a0;months and 81 patients died during follow-up. Tumor primary site, histological type, TNM stage, pathological grading, venous/nervous invasion, extent of TILs, MS/MMR status, pretreatment CEA level and adjuvant therapy in TCGA and FUSCC cohorts are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. In the cohort of TCGA, PD-1 expression was associated with primary site, TILs extent and MS status (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05), whereas PD-L1 expression was correlated with venous invasion, TILs extent, MS status and pretreatment CEA level (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). In the FUSCC cohort, PD-1 expression in TILs was only associated with M stage (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05), whereas PD-L1 expression in TCs was correlated with T stage and M stage (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Comparison of baseline clinicopathological characteristics based on PD-1 and PD-L1 expression of CRC patients in TCGA and FUSCC cohorts</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3"/><th colspan="7">TCGA Cohort (<italic>N</italic>&#x02009;=&#x02009;356)</th><th colspan="6">FUSCC Cohort (<italic>N</italic>&#x02009;=&#x02009;276)</th><th/></tr><tr><th>Cases</th><th colspan="2">PD-1</th><th>
<italic>P</italic>
<sup><italic>a</italic></sup>
</th><th colspan="2">PD-L1</th><th>
<italic>P</italic>
<sup><italic>a</italic></sup>
</th><th>Cases</th><th colspan="2">PD-1</th><th>
<italic>P</italic>
<sup><italic>a</italic></sup>
</th><th colspan="2">PD-L1</th><th>
<italic>P</italic>
<sup><italic>a</italic></sup>
</th></tr><tr><th>No. (%)</th><th>Low</th><th>High</th><th/><th>Low</th><th>High</th><th/><th>No. (%)</th><th>Low</th><th>High</th><th/><th>Low</th><th>High</th><th/></tr></thead><tbody><tr><td colspan="15">Age (years)</td></tr><tr><td>&#x02003;&#x02009;&#x02264;&#x02009;60</td><td>137 (38.5)</td><td>68 (41.2)</td><td>69 (36.1)</td><td>0.325</td><td>21 (38.2)</td><td>116 (38.5)</td><td>0.960</td><td>170 (61.6)</td><td>100 (58.8)</td><td>70 (66.0)</td><td>0.231</td><td>85 (61.6)</td><td>85 (61.6)</td><td rowspan="2">1.000</td></tr><tr><td>&#x02003;&#x02009;&#x0003e;&#x02009;60</td><td>219 (35.7)</td><td>97 (58.8)</td><td>122 (63.9)</td><td/><td>34 (61.8)</td><td>185 (61.5)</td><td/><td>106 (8.4)</td><td>70 (41.7)</td><td>36 (34.0)</td><td/><td>53 (38.4)</td><td>53 (38.4)</td></tr><tr><td colspan="15">Gender</td></tr><tr><td>&#x02003;Male</td><td>199 (55.9)</td><td>91 (55.2)</td><td>108 (56.5)</td><td>0.792</td><td>33 (60.0)</td><td>166 (55.1)</td><td>0.505</td><td>166 (60.1)</td><td>102 (60.0)</td><td>64 (60.4)</td><td>0.950</td><td>88 (63.8)</td><td>78 (56.5)</td><td rowspan="2">0.219</td></tr><tr><td>&#x02003;Female</td><td>157 (44.1)</td><td>74 (44.8)</td><td>83 (43.5)</td><td/><td>22 (40.0)</td><td>135 (44.9)</td><td/><td>110 (39.9)</td><td>68 (40.0)</td><td>42 (39.6)</td><td/><td>50 (36.2)</td><td>60 (43.5)</td></tr><tr><td colspan="15">Primary site</td></tr><tr><td>&#x02003;Colon</td><td>269 (75.6)</td><td>115 (69.7)</td><td>154 (80.6)</td><td>
<italic>0.017</italic>
</td><td>46 (83.6)</td><td>223 (74.1)</td><td>0.130</td><td>129 (46.7)</td><td>84 (49.4)</td><td>45 (42.5)</td><td>0.260</td><td>65 (47.1)</td><td>64 (46.4)</td><td rowspan="2">0.904</td></tr><tr><td>&#x02003;Rectum</td><td>87 (24.4)</td><td>50 (30.3)</td><td>37 (19.4)</td><td/><td>9 (16.4)</td><td>78 (25.9)</td><td/><td>147 (53.3)</td><td>86 (50.6)</td><td>61 (57.5)</td><td/><td>73 (52.9)</td><td>74 (53.6)</td></tr><tr><td colspan="15">Histological type</td></tr><tr><td>&#x02003;Adenocarcinoma</td><td>316 (88.8)</td><td>149 (90.3)</td><td>167 (87.4)</td><td>0.393</td><td>50 (90.9)</td><td>266 (88.4)</td><td>0.584</td><td>261 (94.6)</td><td>158 (92.9)</td><td>103 (97.2)</td><td>0.132</td><td>132 (95.6)</td><td>129 (93.5)</td><td rowspan="2">0.426</td></tr><tr><td>&#x02003;Mucinous/SRCC</td><td>40 (11.2)</td><td>16 (9.7)</td><td>24 (12.6)</td><td/><td>5 (9.1)</td><td>35 (11.6)</td><td/><td>15 (5.4)</td><td>12 (7.1)</td><td>3 (2.8)</td><td/><td>6 (4.3)</td><td>9 (6.5)</td></tr><tr><td colspan="15">T stage</td></tr><tr><td>&#x02003;Tis-T2</td><td>68 (19.1)</td><td>29 (17.6)</td><td>39 (20.4)</td><td>0.386</td><td>9 (16.4)</td><td>78 (25.9)</td><td>0.844</td><td>43 (15.6)</td><td>24 (14.1)</td><td>19 (17.9)</td><td>0.588</td><td>19 (13.8)</td><td>24 (17.4)</td><td rowspan="3">
<italic>0.044</italic>
</td></tr><tr><td>&#x02003;T3</td><td>242 (68.0)</td><td>118 (71.5)</td><td>124 (64.9)</td><td/><td>39 (70.9)</td><td>203 (67.4)</td><td/><td>32 (19.6)</td><td>32 (18.8)</td><td>22 (20.8)</td><td/><td>20 (14.5)</td><td>34 (24.6)</td></tr><tr><td>&#x02003;T4</td><td>46 (12.9)</td><td>18 (10.9)</td><td>28 (14.7)</td><td/><td>7 (12.7)</td><td>39 (13.0)</td><td/><td>179 (64.8)</td><td>114 (67.1)</td><td>65 (61.3)</td><td/><td>99 (71.7)</td><td>80 (58.0)</td></tr><tr><td colspan="15">N stage</td></tr><tr><td>&#x02003;N0</td><td>194 (54.5)</td><td>83 (50.3)</td><td>111 (58.1)</td><td>0.185</td><td>23 (41.8)</td><td>171 (56.8)</td><td>0.101</td><td>120 (43.5)</td><td>70 (41.2)</td><td>50 (47.2)</td><td>0.432</td><td>57 (41.3)</td><td>63 (45.7)</td><td rowspan="3">0.767</td></tr><tr><td>&#x02003;N1</td><td>98 (27.5)</td><td>53 (32.1)</td><td>45 (23.6)</td><td/><td>18 (32.7)</td><td>80 (26.6)</td><td/><td>83 (30.1)</td><td>49 (28.8)</td><td>33 (31.1)</td><td/><td>43 (31.2)</td><td>40 (29.0)</td></tr><tr><td>&#x02003;N2</td><td>64 (18.0)</td><td>29 (17.6)</td><td>35 (18.3)</td><td/><td>14 (25.5)</td><td>50 (16.6)</td><td/><td>73 (26.4)</td><td>50 (29.4)</td><td>23 (21.7)</td><td/><td>38 (27.5)</td><td>35 (25.4)</td></tr><tr><td colspan="15">M stage</td></tr><tr><td>&#x02003;M0</td><td>245 (68.8)</td><td>109 (66.1)</td><td>136 (71.2)</td><td>0.107</td><td>34 (61.8)</td><td>211 (70.1)</td><td>0.284</td><td>234(84.8)</td><td>137 (80.6)</td><td>97 (91.5)</td><td>
<italic>0.01</italic>
</td><td>108(78.3)</td><td>126 (91.3)</td><td rowspan="3">
<italic>0.003</italic>
</td></tr><tr><td>&#x02003;M1</td><td>48 (13.5)</td><td>29 (17.6)</td><td>19 (9.9)</td><td/><td>11 (20.0)</td><td>37 (12.3)</td><td/><td>42(15.2)</td><td>33 (19.4)</td><td>9 (8.5)</td><td/><td>30(21.7)</td><td>12 (8.7)</td></tr><tr><td>&#x02003;Mx</td><td>63 (17.7)</td><td>27 (16.4)</td><td>36 (18.8)</td><td/><td>10 (18.2)</td><td>53 (17.6)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan="15">Pathological grading</td></tr><tr><td>&#x02003;Well/moderate</td><td rowspan="3" colspan="7">NA</td><td>204(73.9)</td><td>67 (73.6)</td><td>137 (74.1)</td><td>0.498</td><td>102(73.9)</td><td>102 (73.9)</td><td rowspan="3">1.000</td></tr><tr><td>&#x02003;Poor/anaplastic</td><td>56(20.3)</td><td>18 (19.8)</td><td>38 (20.5)</td><td/><td>28(20.3)</td><td>28 (20.3)</td></tr><tr><td>&#x02003;Unknown</td><td>16(5.8)</td><td>6 (6.6)</td><td>10 (5.4)</td><td/><td>8(5.8)</td><td>8 (5.8)</td></tr><tr><td colspan="15">Venous invasion</td></tr><tr><td>&#x02003;Negative</td><td>235 (66.0)</td><td>105 (63.6)</td><td>130 (68.1)</td><td>0.557</td><td>28 (50.9)</td><td>207 (68.8)</td><td>
<italic>0.026</italic>
</td><td>184(66.7)</td><td>107 (62.9)</td><td>77 (72.6)</td><td>0.104</td><td>85(61.6)</td><td>99 (71.7)</td><td rowspan="3">0.193</td></tr><tr><td>&#x02003;Positive</td><td>70 (19.7)</td><td>33 (20.0)</td><td>37 (19.4)</td><td/><td>14 (25.5)</td><td>56 (18.6)</td><td/><td>88(31.9)</td><td>59 (34.7)</td><td>29 (27.4)</td><td/><td>51(37.0)</td><td>37 (26.8)</td></tr><tr><td>&#x02003;Unknown</td><td>51 (14.3)</td><td>27 (16.4)</td><td>24 (12.6)</td><td/><td>13 (23.6)</td><td>38 (12.6)</td><td/><td>4(1.4)</td><td>4 (2.4)</td><td>0 (0.0)</td><td/><td>2(1.4)</td><td>2 (1.4)</td></tr><tr><td colspan="15">Nervous invasion</td></tr><tr><td>&#x02003;Negative</td><td rowspan="2" colspan="7">NA</td><td>231 (83.7)</td><td>75 (82.4)</td><td>156 (84.3)</td><td>0.181</td><td>118 (85.5)</td><td>231 (83.7)</td><td rowspan="2">0.337</td></tr><tr><td>&#x02003;Positive</td><td>45 (16.3)</td><td>16 (17.6)</td><td>29 (15.7)</td><td/><td>20 (14.5)</td><td>45 (16.3)</td></tr><tr><td colspan="15">TILs extent</td></tr><tr><td>&#x02003;Low</td><td>47 (13.2)</td><td>33 (20.0)</td><td>14 (7.3)</td><td>
<italic>0.002</italic>
</td><td>16 (29.1)</td><td>31 (10.3)</td><td>
<italic>&#x0003c;0.001</italic>
</td><td>129 (46.7)</td><td>85 (50.0)</td><td>44 (41.5)</td><td>0.169</td><td>59 (42.8)</td><td>70 (50.7)</td><td rowspan="3">0.184</td></tr><tr><td>&#x02003;High</td><td>93 (26.1)</td><td>42 (25.5)</td><td>51 (26.3)</td><td/><td>17 (30.9)</td><td>76 (25.2)</td><td/><td>147 (53.3)</td><td>85 (50.0)</td><td>62 (58.5)</td><td/><td>79 (57.2)</td><td>68 (49.3)</td></tr><tr><td>&#x02003;Unknown</td><td>216 (60.7)</td><td>90 (54.5)</td><td>126 (66.0)</td><td/><td>22 (40.0)</td><td>194 (64.5)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan="15">No. of LNs dissected</td></tr><tr><td>&#x02003;&#x02009;&#x0003c;&#x02009;12</td><td>80 (22.5)</td><td>42 (25.5)</td><td>38 (19.9)</td><td>0.219</td><td>14 (25.5)</td><td>56 (18.6)</td><td>0.658</td><td>39 (14.1)</td><td>24 (14.1)</td><td>15 (14.2)</td><td>0.994</td><td>16 (11.6)</td><td>23 (16.7)</td><td rowspan="3">0.226</td></tr><tr><td>&#x02003;&#x02009;&#x02265;&#x02009;12</td><td>247 (69.4)</td><td>107(64.8)</td><td>140 (73.3)</td><td/><td>38 (69.1)</td><td>209 (69.4)</td><td/><td>237 (85.9)</td><td>146 (85.9)</td><td>91 (85.8)</td><td/><td>122 (88.4)</td><td>115 (83.3)</td></tr><tr><td>&#x02003;Unknown</td><td>29 (8.1)</td><td>16 (9.7)</td><td>13 (6.8)</td><td/><td>3 (5.5)</td><td>26 (8.6)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan="15">MS status/MMR status</td></tr><tr><td>&#x02003;MSS/MMR-proficient</td><td>243 (68.3)</td><td>123 (74.5)</td><td>120 (62.8)</td><td>
<italic>0.018</italic>
</td><td>39 (70.9)</td><td>204 (67.8)</td><td>0.646</td><td>176 (63.8)</td><td>102 (60.0)</td><td>74 (69.8)</td><td>0.099</td><td>93 (67.4)</td><td>83 (60.1)</td><td rowspan="2">0.21</td></tr><tr><td>&#x02003;MSI/MMR-deficient</td><td>113 (31.7)</td><td>42 (25.5)</td><td>71 (37.2)</td><td/><td>16 (29.1)</td><td>97 (32.2)</td><td/><td>100 (36.2)</td><td>68 (40.0)</td><td>32 (30.2)</td><td/><td>45 (32.6)</td><td>55 (39.9)</td></tr><tr><td colspan="15">CEA (&#x003bc;l/ml)</td></tr><tr><td>&#x02003;&#x02009;&#x02264;&#x02009;5</td><td>144 (40.4)</td><td>59 (35.8)</td><td>85 (44.5)</td><td>0.151</td><td>13 (23.6)</td><td>131 (43.5)</td><td>
<italic>0.007</italic>
</td><td>170 (61.6)</td><td>106 (62.4)</td><td>64 (60.4)</td><td>0.532</td><td>80 (58.0)</td><td>90 (65.2)</td><td rowspan="3">0.382</td></tr><tr><td>&#x02003;&#x02009;&#x0003e;&#x02009;5</td><td>85 (23.9)</td><td>39 (23.6)</td><td>46 (24.1)</td><td/><td>13 (23.6)</td><td>72 (23.9)</td><td/><td>95 (34.4)</td><td>59 (34.7)</td><td>36 (34.0)</td><td/><td>51 (37.0)</td><td>44 (31.9)</td></tr><tr><td>&#x02003;Unknown</td><td>127 (35.7)</td><td>67 (40.6)</td><td>60 (31.4)</td><td/><td>29 (52.7)</td><td>98 (32.6)</td><td/><td>11 (4.0)</td><td>5 (2.9)</td><td>6 (5.7)</td><td/><td>7 (5.1)</td><td>4 (2.9)</td></tr><tr><td colspan="15">Adjuvant chemotherapy</td></tr><tr><td>&#x02003;Yes</td><td rowspan="3" colspan="7">NA</td><td>189 (68.5)</td><td>58 (63.7)</td><td>131 (70.8)</td><td>0.082</td><td>89 (64.5)</td><td>100 (72.5)</td><td rowspan="3">0.05</td></tr><tr><td>&#x02003;No</td><td>49 (17.8)</td><td>15 (16.5)</td><td>34 (18.4)</td><td/><td>23 (16.7)</td><td>26 (18.8)</td></tr><tr><td>&#x02003;Unknown</td><td>38 (13.7)</td><td>18 (19.8)</td><td>20 (10.8)</td><td/><td>26 (18.8)</td><td>12 (8.7)</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>Italic entries indicate statistical significance</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>Expression pattern of PD-1 and PD-L1</title><p>In the TCGA cohort, the cut-off values of PD-1 and PD-L1 mRNA levels in tumor tissue of eligible patients were determined by X-tile program, which were 4.40 and 2.92, respectively (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). The &#x003c7;<sup>2</sup> log-rank value of PD-1 and PD-L1 were 4.591 and 9.349, respectively. Patients were divided into 2 groups for further analysis (PD-1&#x02009;&#x02264;&#x02009;4.40 and &#x0003e;4.40, PD-L1&#x02009;&#x02264;&#x02009;2.92 and &#x0003e;2.92).<fig id="Fig1"><label>Fig. 1</label><caption><p>Determination of cut-off values of PD-1 and PD-L1 expressions in TCGA database and survival analyses. X-tile analysis of 5-year OS was performed using patients&#x02019; data in TCGA database to determine the optimal cut-off value for PD-1 and PD-L1 expression. The sample of CRC patients was equally divided into training and validation sets. X-tile plots of training sets are shown in the <italic>left panels</italic>, with plots of matched validation sets shown in the <italic>smaller inset</italic>. The optimal cut-off values highlighted by the <italic>black circles</italic> in <italic>left panels</italic> are shown in histograms of the entire cohort (<italic>middle panels</italic>), and Kaplan-Meier plots are displayed in <italic>right panels. P</italic> values were determined by using the cut-off values defined in training sets and applying them to validation sets. <bold>a</bold> The optimal cut-off value for PD-1 was 4.40 (&#x003c7;<sup>2</sup>&#x02009;=&#x02009;4.591, <italic>P</italic>&#x02009;=&#x02009;0.032). <bold>b</bold> The optimal cut-off value for PD-L1 was 2.92 (&#x003c7;<sup>2</sup>&#x02009;=&#x02009;9.349, <italic>P</italic>&#x02009;=&#x02009;0.002)</p></caption><graphic xlink:href="12943_2016_539_Fig1_HTML" id="MO1"/></fig></p><p>In the FUSCC cohort, the expressions of PD-1 in TILs and PD-L1 in tumor cells (TCs) were detected by IHC staining. PD-L1 showed a membrane-accentuated expression, while PD-1 also displayed a membrane-accentuated expression, which was often accompanied by a cytoplasmic expression (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). For further analysis, patients were divided into two groups with low expression of PD-1/PD-L1 (IRS&#x02009;&#x02264;&#x02009;4) and high expression of them (IRS&#x02009;&#x0003e;&#x02009;4). In 106 CRC patients (38.4&#x000a0;%), a high expression of PD-1 in TILs was observed and in 170 cases (61.6&#x000a0;%), PD-1 expression in TILs was low. While half of the cases in this cohort displayed a high expression of PD-L1 in TCs, and the other half showed a low expression of it.<fig id="Fig2"><label>Fig. 2</label><caption><p>IHC staining of PD-L1 and PD-1 expressions in TMA samples. PD-1 displayed a membrane-accentuated expression, which was often accompanied by a cytoplasmic expression (<bold>b</bold>), while PD-L1showed a membrane-accentuated expression (<bold>d</bold>). Tumor infiltrating lymphocytes were indicated by <italic>red arrows</italic>. The&#x000a0;representative pictures of&#x000a0;negative expression of PD-1/PD-L1 were also shown (<bold>a</bold>, <bold>c</bold>)</p></caption><graphic xlink:href="12943_2016_539_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec12"><title>Prognostic significance of PD-1 and PD-L1 expression</title><p>In the TCGA cohort, the univariate Cox regression model revealed that TNM stages, venous invasion, pretreatment CEA level, PD-1 and PD-L1 expressions were associated with prognosis of CRC patients in terms of OS (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Multivariate analysis after adjustment indicated that only T stage and pretreatment CEA level were independent prognostic factors for OS in CRC patients (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05) and PD-1 and PD-L1 expression lost their significance (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Univariate and multivariate Cox proportional hazards analysis of OS for patients with CRC in the TCGA cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variables<sup>a</sup>
</th><th>Univariate analysis HR (95 % CI)</th><th>
<italic>P</italic>
<sup><italic>b</italic></sup>
</th><th>Multivariate analysis HR (95 % CI)</th><th>
<italic>P</italic>
<sup><italic>b</italic></sup>
</th></tr></thead><tbody><tr><td colspan="5">Age (years)</td></tr><tr><td>&#x02003;&#x02009;&#x02264;&#x02009;60</td><td>1.000</td><td>0.202</td><td>1.000</td><td rowspan="2">0.937</td></tr><tr><td>&#x02003;&#x02009;&#x0003e;&#x02009;60</td><td>1.366 (0.846&#x02013;2.204)</td><td/><td>1.021 (0.606&#x02013;1.720)</td></tr><tr><td colspan="5">Gender</td></tr><tr><td>&#x02003;Male</td><td>1.000</td><td>0.132</td><td>1.000</td><td rowspan="2">0.205</td></tr><tr><td>&#x02003;Female</td><td>0.687 (0.421&#x02013;1.120)</td><td/><td>0.718 (0.431&#x02013;1.198)</td></tr><tr><td colspan="5">Tumor location</td></tr><tr><td>&#x02003;Colon</td><td>1.000</td><td>0.149</td><td/><td rowspan="2"/></tr><tr><td>&#x02003;Rectum</td><td>0.580 (0.277&#x02013;1.215)</td><td/><td/></tr><tr><td colspan="5">Histological type</td></tr><tr><td>&#x02003;Adenocarcinoma</td><td>1.000</td><td>0.148</td><td/><td rowspan="2"/></tr><tr><td>&#x02003;Mucinous/SRCC</td><td>1.611 (0.844&#x02013;3.076)</td><td/><td/></tr><tr><td colspan="5">T stage</td></tr><tr><td>&#x02003;Tis-T2</td><td>1.000</td><td>
<italic>&#x0003c;0.001</italic>
</td><td>1.000</td><td rowspan="3">
<italic>&#x0003c;0.001</italic>
</td></tr><tr><td>&#x02003;T3</td><td>1.463 (0.618&#x02013;3.465)</td><td/><td>0.832 (0.330&#x02013;2.053)</td></tr><tr><td>&#x02003;T4</td><td>8.584 (3.316&#x02013;22.222)</td><td/><td>2.912 (1.242&#x02013;8.093)</td></tr><tr><td colspan="5">N stage</td></tr><tr><td>&#x02003;N0</td><td>1.000</td><td>
<italic>&#x0003c;0.001</italic>
</td><td>1.000</td><td rowspan="3">0.583</td></tr><tr><td>&#x02003;N1</td><td>2.311 (1.306&#x02013;4.091)</td><td/><td>1.430 (0.724&#x02013;2.823)</td></tr><tr><td>&#x02003;N2</td><td>3.098 (1.718&#x02013;5.588)</td><td/><td>1.213 (0.557&#x02013;2.642)</td></tr><tr><td colspan="5">M stage</td></tr><tr><td>&#x02003;M0</td><td>1.000</td><td>
<italic>&#x0003c;0.001</italic>
</td><td>1.000</td><td rowspan="3">0.115</td></tr><tr><td>&#x02003;M1</td><td>4.013 (2.252&#x02013;7.152)</td><td/><td>2.062 (1.007&#x02013;4.221)</td></tr><tr><td>&#x02003;Mx</td><td>1.996 (1.083&#x02013;3.676)</td><td/><td>1.701 (0.837&#x02013;3.458)</td></tr><tr><td colspan="5">Venous invasion</td></tr><tr><td>&#x02003;Negative</td><td>1.000</td><td>
<italic>0.006</italic>
</td><td>1.000</td><td rowspan="3">0.145</td></tr><tr><td>&#x02003;Positive</td><td>2.411 (1.400&#x02013;4.151)</td><td/><td>2.008 (1.000&#x02013;4.033)</td></tr><tr><td>&#x02003;Unknown</td><td>1.625 (0.842&#x02013;3.137)</td><td/><td>1.362 (0.655&#x02013;2.830)</td></tr><tr><td colspan="5">TILs extent</td></tr><tr><td>&#x02003;Low</td><td>1.000</td><td>0.541</td><td/><td rowspan="3"/></tr><tr><td>&#x02003;High</td><td>0.746 (0.357&#x02013;1.558)</td><td/><td/></tr><tr><td>&#x02003;Unknown</td><td>0.737 (0.422&#x02013;1.286)</td><td/><td/></tr><tr><td colspan="5">No. of LNs dissected</td></tr><tr><td>&#x02003;&#x02009;&#x0003c;&#x02009;12</td><td>1.000</td><td>0.145</td><td/><td rowspan="3"/></tr><tr><td>&#x02003;&#x02009;&#x02265;&#x02009;12</td><td>2.311 (0.542&#x02013;9.853)</td><td/><td/></tr><tr><td>&#x02003;Unknown</td><td>1.432 (0.347&#x02013;5.917)</td><td/><td/></tr><tr><td colspan="5">MS status</td></tr><tr><td>&#x02003;MSS</td><td>1.000</td><td/><td/><td rowspan="2"/></tr><tr><td>&#x02003;MSI</td><td>1.159 (0.710&#x02013;1.892)</td><td>0.557</td><td/></tr><tr><td colspan="5">CEA (&#x003bc;l/ml)</td></tr><tr><td>&#x02003;&#x02009;&#x02264;&#x02009;5</td><td>1.000</td><td/><td>1.000</td><td rowspan="3">
<italic>0.011</italic>
</td></tr><tr><td>&#x02003;&#x02009;&#x0003e;&#x02009;5</td><td>2.146 (0.978&#x02013;4.708)</td><td>
<italic>0.003</italic>
</td><td>1.339 (0.582&#x02013;3.081)</td></tr><tr><td>&#x02003;Unknown</td><td>3.086 (1.617&#x02013;5.891)</td><td/><td>2.778 (1.337&#x02013;5.772)</td></tr><tr><td colspan="5">PD-1</td></tr><tr><td>&#x02003;Low</td><td>1.000</td><td/><td>1.000</td><td rowspan="2">0.68</td></tr><tr><td>&#x02003;High</td><td>0.591 (0.364&#x02013;0.961)</td><td>
<italic>0.034</italic>
</td><td>0.883 (0.488&#x02013;1.596)</td></tr><tr><td colspan="5">PD-L1</td></tr><tr><td>&#x02003;Low</td><td>1.000</td><td/><td>1.000</td><td rowspan="2">0.148</td></tr><tr><td>&#x02003;High</td><td>0.463 (0.279&#x02013;0.768)</td><td>
<italic>0.003</italic>
</td><td>0.626 (0.332&#x02013;1.181)</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>All variables are djusted by Cox proportional hazards models including age, gender, T stage, N stage and M stage</p><p>
<sup>b</sup>Italic entries indicate statistical significance</p></table-wrap-foot></table-wrap></p><p>In the FUSCC cohort, Kaplan-Meier analysis showed that both the expression of PD-1 in TILs and the expression of PD-L1 in TCs were associated with OS and DFS of CRC patients (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>&#x02013;<xref rid="Fig3" ref-type="fig">d</xref>). The univariate Cox regression model indicated that TNM stages, venous invasion, pretreatment CEA level, adjuvant chemotherapy, TILs-PD-1 and TCs-PD-L1 expressions were correlated with OS (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05), whereas TNM stages, venous invasion, nervous invasion, pretreatment CEA level, adjuvant chemotherapy, TILs-PD-1 and TCs-PD-L1 expressions were associated with DFS. Multivariate analysis after adjustment revealed that T stage, M stage, pretreatment CEA level, adjuvant chemotherapy and TILs-PD-1 were independent prognostic factors for OS, while only T stage, M stage and TILs-PD-1 were independent prognostic factor for DFS of CRC patients&#x000a0;(Table <xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Univariate and multivariate Cox proportional hazards analysis of OS and DFS for patients with CRC in the FUSCC cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3">Variables<sup>a</sup>
</th><th colspan="4">OS</th><th colspan="4">DFS</th></tr><tr><th>Univariate analysis</th><th>
<italic>P</italic>
<sup><italic>b</italic></sup>
</th><th>Multivariate analysis</th><th>
<italic>P</italic>
<sup><italic>b</italic></sup>
</th><th>Univariate analysis</th><th>
<italic>P</italic>
<sup><italic>b</italic></sup>
</th><th>Multivariate analysis</th><th>
<italic>P</italic>
<sup><italic>b</italic></sup>
</th></tr><tr><th>HR (95 % CI)</th><th/><th>HR (95 % CI)</th><th/><th>HR (95 % CI)</th><th/><th>HR (95 % CI)</th><th/></tr></thead><tbody><tr><td colspan="9">Age (years)</td></tr><tr><td>&#x02003;&#x02009;&#x02264;&#x02009;60</td><td>1.000</td><td>0.367</td><td>1.000</td><td>0.564</td><td>1.000</td><td>0.593</td><td>1.000</td><td rowspan="2">0.633</td></tr><tr><td>&#x02003;&#x02009;&#x0003e;&#x02009;60</td><td>1.224 (0.789&#x02013;1.900)</td><td/><td>1.154 (0.709&#x02013;1.879)</td><td/><td>1.115 (0.749&#x02013;1.661)</td><td/><td>1.113 (0.717&#x02013;1.730)</td></tr><tr><td colspan="9">Gender<sup>b</sup>
</td></tr><tr><td>&#x02003;Male</td><td>1.000</td><td>0.418</td><td>1.000</td><td>0.493</td><td>1.000</td><td>0.238</td><td>1.000</td><td rowspan="2">0.305</td></tr><tr><td>&#x02003;Female</td><td>0.829 (0.526&#x02013;1.306)</td><td/><td>0.843 (0.518&#x02013;1.374)</td><td/><td>0.781 (0.518&#x02013;1.178)</td><td/><td>0.793 (0.509&#x02013;1.235)</td></tr><tr><td colspan="9">Tumor location</td></tr><tr><td>&#x02003;Colon</td><td>1.000</td><td>0.061</td><td/><td/><td>1.000</td><td>0.223</td><td/><td rowspan="2"/></tr><tr><td>&#x02003;Rectum</td><td>0.658 (0.424&#x02013;1.020)</td><td/><td/><td/><td>0.784 (0.529&#x02013;1.160)</td><td/><td/></tr><tr><td colspan="9">Histological type</td></tr><tr><td>&#x02003;Adenocarcinoma</td><td>1.000</td><td>0.781</td><td/><td/><td>1.000</td><td>0.765</td><td/><td rowspan="2"/></tr><tr><td>&#x02003;Mucinous/SRCC</td><td>0.867 (0.317&#x02013;2.369)</td><td/><td/><td/><td>0.872 (0.355&#x02013;2.143)</td><td/><td/></tr><tr><td colspan="9">T stage</td></tr><tr><td>&#x02003;Tis-T2</td><td>1.000</td><td>
<italic>&#x0003c;0.001</italic>
</td><td>1.000</td><td>
<italic>0.017</italic>
</td><td>1.000</td><td>
<italic>&#x0003c;0.001</italic>
</td><td>1.000</td><td rowspan="3">
<italic>0.032</italic>
</td></tr><tr><td>&#x02003;T3</td><td>4.450 (0.975&#x02013;20.312)</td><td/><td>6.329 (1.325&#x02013;30.238)</td><td/><td>2.979 (0.971&#x02013;9.138)</td><td/><td>3.471 (1.074&#x02013;11.221)</td></tr><tr><td>&#x02003;T4</td><td>10.534 (2.581&#x02013;42.992)</td><td/><td>8.734 (1.948&#x02013;39.161)</td><td/><td>6.524 (2.390&#x02013;17.805)</td><td/><td>4.282 (1.443&#x02013;12.710)</td></tr><tr><td colspan="9">N stage</td></tr><tr><td>&#x02003;N0</td><td>1.000</td><td>
<italic>&#x0003c;0.001</italic>
</td><td>1.000</td><td>0.269</td><td>1.000</td><td>
<italic>&#x0003c;0.001</italic>
</td><td>1.000</td><td rowspan="3">0.089</td></tr><tr><td>&#x02003;N1</td><td>2.770 (1.537&#x02013;4.992)</td><td/><td>2.011 (0.982&#x02013;4.117)</td><td/><td>2.927 (1.721&#x02013;4.979)</td><td/><td>2.251 (1.202&#x02013;4.215)</td></tr><tr><td>&#x02003;N2</td><td>4.146 (2.336&#x02013;7.357)</td><td/><td>1.931 (0.903&#x02013;4.130)</td><td/><td>4.212 (2.510&#x02013;7.069)</td><td/><td>1.968 (0.984&#x02013;3.934)</td></tr><tr><td colspan="9">M stage</td></tr><tr><td>&#x02003;M0</td><td>1.000</td><td>
<italic>&#x0003c;0.001</italic>
</td><td>1.000</td><td>
<italic>0.024</italic>
</td><td>1.000</td><td>
<italic>&#x0003c;0.001</italic>
</td><td>1.000</td><td rowspan="2">
<italic>&#x0003c;0.001</italic>
</td></tr><tr><td>&#x02003;M1</td><td>9.094 (5.757&#x02013;14.367)</td><td/><td>2.833 (1.137&#x02013;6.083)</td><td/><td>10.198 (6.648&#x02013;15.642)</td><td/><td>4.377 (1.999&#x02013;9.585)</td></tr><tr><td colspan="9">Pathological grading</td></tr><tr><td>&#x02003;Well/moderate</td><td>1.000</td><td>0.378</td><td/><td/><td>1.000</td><td>0.729</td><td/><td rowspan="2"/></tr><tr><td>&#x02003;Poor/anaplastic</td><td>1.278 (0.762&#x02013;2.144)</td><td/><td/><td/><td>1.137 (0.706&#x02013;1.832)</td><td/><td/></tr><tr><td>&#x02003;Unknown</td><td>0.576 (0.180&#x02013;1.836)</td><td/><td/><td/><td>0.784 (0.317&#x02013;1.941)</td><td/><td/><td/></tr><tr><td colspan="9">Venous invasion</td></tr><tr><td>&#x02003;Negative</td><td>1.000</td><td>
<italic>&#x0003c;0.001</italic>
</td><td>1.000</td><td>0.987</td><td>1.000</td><td>
<italic>&#x0003c;0.001</italic>
</td><td>1.000</td><td rowspan="3">0.55</td></tr><tr><td>&#x02003;Positive</td><td>2.448 (1.578&#x02013;3.796)</td><td/><td>0.986 (0.578&#x02013;1.681)</td><td/><td>2.216 (1.492&#x02013;3.291)</td><td/><td>0.760 (0.464&#x02013;1.246)</td></tr><tr><td>&#x02003;Unknown</td><td>1.043 (0.143&#x02013;7.587)</td><td/><td>1.163 (0.154&#x02013;8.756)</td><td/><td>0.813 (0.112&#x02013;5.884)</td><td/><td>0.821 (0.110&#x02013;6.136)</td></tr><tr><td colspan="9">Nervous invasion</td></tr><tr><td>&#x02003;Negative</td><td>1.000</td><td>0.059</td><td/><td/><td>1.000</td><td>
<italic>0.008</italic>
</td><td>1.000</td><td rowspan="2">0.199</td></tr><tr><td>&#x02003;Positive</td><td>1.641 (0.981&#x02013;2.743)</td><td/><td/><td/><td>1.186 (1.175&#x02013;2.949)</td><td/><td>1.375 (0.846&#x02013;2.237)</td></tr><tr><td colspan="9">No. of LNs dissected</td></tr><tr><td>&#x02003;&#x02009;&#x0003c;&#x02009;12</td><td>1.000</td><td>0.249</td><td/><td/><td>1.000</td><td>0.297</td><td/><td rowspan="2"/></tr><tr><td>&#x02003;&#x02009;&#x02265;&#x02009;12</td><td>0.719 (0.410&#x02013;1.260)</td><td/><td/><td/><td>0.757 (0.449&#x02013;1.276)</td><td/><td/></tr><tr><td colspan="9">MMR status</td></tr><tr><td>&#x02003;MMR-proficient</td><td>1.000</td><td>0.726</td><td/><td/><td>1.000</td><td>0.792</td><td/><td rowspan="2"/></tr><tr><td>&#x02003;MMR-deficient</td><td>1.084 (0.692&#x02013;1.696)</td><td/><td/><td/><td>0.947 (0.632&#x02013;1.418)</td><td/><td/></tr><tr><td colspan="9">CEA (&#x003bc;l/ml)</td></tr><tr><td>&#x02003;&#x02009;&#x02264;&#x02009;5</td><td>1.000</td><td>
<italic>&#x0003c;0.001</italic>
</td><td>1.000</td><td>
<italic>0.041</italic>
</td><td>1.000</td><td>
<italic>&#x0003c;0.001</italic>
</td><td>1.000</td><td rowspan="3">0.096</td></tr><tr><td>&#x02003;&#x02009;&#x0003e;&#x02009;5</td><td>2.468 (1.572&#x02013;3.875)</td><td/><td>1.386 (0.824&#x02013;2.331)</td><td/><td>2.768 (1.845&#x02013;4.152)</td><td/><td>1.529 (0.956&#x02013;2.444)</td></tr><tr><td>&#x02003;Unknown</td><td>2.850 (1.118&#x02013;7.265)</td><td/><td>3.513 (1.292&#x02013;9.558)</td><td/><td>2.472 (0.979&#x02013;6.246)</td><td/><td>2.230 (0.848&#x02013;5.863)</td></tr><tr><td colspan="9">Adjuvant chemotherapy</td></tr><tr><td>&#x02003;Yes</td><td>1.000</td><td>
<italic>&#x0003c;0.001</italic>
</td><td>1.000</td><td>
<italic>0.019</italic>
</td><td>1.000</td><td>
<italic>&#x0003c;0.001</italic>
</td><td>1.000</td><td rowspan="3">0.366</td></tr><tr><td>&#x02003;No</td><td>0.670 (0.315&#x02013;1.425)</td><td/><td>1.835 (0.735&#x02013;4.584)</td><td/><td>0.568 (0.281&#x02013;1.146)</td><td/><td>1.419 (0.609&#x02013;3.307)</td></tr><tr><td>&#x02003;Unknown</td><td>8.344 (5.142&#x02013;13.542)</td><td/><td>3.130 (1.345&#x02013;7.282)</td><td/><td>6.990 (4.495&#x02013;10.870)</td><td/><td>1.645 (0.755&#x02013;3.584)</td></tr><tr><td colspan="9">TILs-PD-1</td></tr><tr><td>&#x02003;Low</td><td>1.000</td><td>
<italic>0.007</italic>
</td><td>1.000</td><td>
<italic>0.006</italic>
</td><td>1.000</td><td>
<italic>0.003</italic>
</td><td>1.000</td><td rowspan="2">
<italic>0.015</italic>
</td></tr><tr><td>&#x02003;High</td><td>0.500 (0.302&#x02013;0.828)</td><td/><td>0.480 (0.283&#x02013;0.814)</td><td/><td>0.502 (0.319&#x02013;0.789)</td><td/><td>0.559 (0.350&#x02013;0.893)</td></tr><tr><td colspan="9">TCs-PD-L1</td></tr><tr><td>&#x02003;Low</td><td>1.000</td><td>
<italic>0.027</italic>
</td><td>1.000</td><td>0.852</td><td>1.000</td><td>
<italic>0.005</italic>
</td><td>1.000</td><td rowspan="2">0.66</td></tr><tr><td>&#x02003;High</td><td>0.606 (0.389&#x02013;0.944)</td><td/><td>1.048 (0.639&#x02013;1.719)</td><td/><td>0.558 (0.373&#x02013;0.835)</td><td/><td>0.904 (0.577&#x02013;1.417)</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>All variables are djusted by Cox proportional hazards models including age, gender, T stage, N stage and M stage</p><p>
<sup>b</sup>Italic entries indicate statistical significance</p></table-wrap-foot></table-wrap><fig id="Fig3"><label>Fig. 3</label><caption><p>Kaplan Meier analyses for TILs-PD-1/TCs-PD-L1 expression and their correlation with clinical outcome in FUSCC cohort. <bold>a</bold> OS according to TILs-PD-1; <bold>b</bold> DFS according to TILs-PD-1; <bold>c</bold> OS according to TCs-PD-L1; <bold>d</bold> DFS according to TCs-PD-L1</p></caption><graphic xlink:href="12943_2016_539_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec13"><title>Subgroup analyses of TILs-PD-1 and TCs-PD-L1 expression according to MMR status&#x000a0;in FUSCC cohort</title><p>Previous studies indicated that active immune microenvironment was observed in MSI/MMR-deficient tumors [<xref ref-type="bibr" rid="CR19">19</xref>], which may lead to a better prognosis of CRC patients. And it was reported that only microsatellite instable (MSI) subset of CRC seems to be a good candidate for checkpoint blockage immunotherapy [<xref ref-type="bibr" rid="CR3">3</xref>] and the mechanisms are still controversial. Thus, we further made subgroup analyses of PD-1 and PD-L1 expressions according to patients&#x02019; MMR status in FUSCC cohort. Kaplan-Meier analysis indicated that both TILs-PD-1 and TCs-PD-L1 correlated with OS and DFS (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4a</xref>&#x02013;<xref rid="Fig4" ref-type="fig">d</xref>) in MSS-proficient subgroup while neither of TILs-PD-1 and TCs-PD-L1 correlated with OS or DFS in MSS-deficient subgroup (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05, Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4e</xref>&#x02013;<xref rid="Fig4" ref-type="fig">h</xref>). In the MSS-proficient subgroup, the univariate Cox regression model revealed that TNM stages, adjuvant chemotherapy, TILs-PD-1 and TCs-PD-L1 expressions were associated with prognosis of CRC patients in terms of OS (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1), whereas TNM stages, venous and nervous invasion, pretreatment CEA level, adjuvant chemotherapy, TILs-PD-1 and TCs-PD-L1 expressions were associated with prognosis of CRC patients in terms of DFS (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). However, multivariate analysis after adjustment indicated that only TILs-PD-1 was an independent prognostic factor for OS and only M stage and TILs-PD-1 were independent prognostic factors for DFS in CRC patients (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). In the MSS-deficient subgroup, the Cox regression model revealed that neither of TILs-PD-1 and TCs-PD-L1 was an independent prognostic factor for OS or DFS in CRC patients (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S2).<fig id="Fig4"><label>Fig. 4</label><caption><p>Subgroup analyses using Kaplan Meier method for TILs-PD-1/TCs-PD-L1 expression and their correlation with clinical outcome in FUSCC cohort. <bold>a</bold> OS according to TILs-PD-1 in MMR-proficient subgroup; <bold>b</bold> OS according to TCs-PD-L1 in MMR-proficient subgroup; <bold>c</bold> DFS according to TILs-PD-1 in MMR-proficient subgroup; <bold>d</bold> DFS according to TCs-PD-L1 in MMR-proficient subgroup; <bold>e</bold> OS according to TILs-PD-1 in MMR-deficient subgroup; <bold>f</bold> OS according to TCs-PD-L1&#x000a0;in MMR-deficient subgroup; <bold>g</bold> DFS according to TILs-PD-1&#x000a0;in MMR-deficient subgroup; <bold>h</bold> DFS according to TCs-PD-L1 in MMR-deficient subgroup</p></caption><graphic xlink:href="12943_2016_539_Fig4_HTML" id="MO4"/></fig></p></sec></sec><sec id="Sec14"><title>Discussion</title><p>PD-1/PD-L1 axis, as an immune checkpoint, is usually up-regulated to create an immunosuppressive tumor microenvironment and help cancer cells escape immune-mediated destruction [<xref ref-type="bibr" rid="CR20">20</xref>]. Previous studies indicated that the correlations between PD-L1 and prognosis are variant among different tumor types [<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref>]. For colorectal cancer, Droeser RA et al. found that PD-L1 expression is paradoxically associated with improved survival in MMR-proficient CRC [<xref ref-type="bibr" rid="CR25">25</xref>]. However, the expression of PD-1 was not analyzed in their study. Our study aimed at systematically analyzing the expression of PD-1 and PD-L1 in colorectal cancer cells and tumor infiltrating cells, and their clinical significance, adopting TCGA database and the FUSCC cohort of patients. We found that the high expression of PD-1 or PD-L1 were associated with better prognosis of CRC patients and PD-1 expression in TILs was an independent prognostic factor for OS and DFS of CRC patients, specifically for patients in MMR-proficient status.</p><p>We firstly used TCGA database to investigate the relationship between the expression of PD-1/PD-L1 and clinical outcome. To begin with, X-tile program, a robust graphic tool, was adopted to identify the optimal cut-off values of PD-1 and PD-L1 levels. The Kaplan-Meier analysis revealed the positive correlation of higher PD-1/PD-L1 expression and better OS of CRC patients, lying the basis of our study. However, the PD-1/PD-L1 level in TCGA database was detected by RNA sequencing using the whole RNA extracted in tumor tissue quantifying expression level of both TCs and TILs. In fact, PD-1 and PD-L1 are expressed in two tumoral compartments, tumor cells and TILs respectively, and their interaction may cause changes in tumor microenvironment, leading to different results of tumor progression. Thus, TILs-PD-1 and TCs-PD-L1 were then analyzed separately by IHC detection based on a relatively large TMA sample in FUSCC to verify the results in TCGA database. Consistently, both of the biomarkers were associated with better OS and DFS of CRC patients.</p><p>Currently, the expression of PD-L1 on TCs is regarded as an immune-tolerance mechanism of the tumor, as it can attract PD-1 expressing immune-inhibitory TILs. However, this mechanism is expected to result into a negative correlation of TILs-PD-1/TCs-PD-L1 expression and survival, as it was reported, e.g. for renal cell carcinoma, breast cancer, non-small cell lung cancer [<xref ref-type="bibr" rid="CR24">24</xref>] and osteosarcoma [<xref ref-type="bibr" rid="CR26">26</xref>]. Of note, the present study is not the only one to report a favorable prognostic impact of TILs-PD-1/TCs-PD-L1 expression in cancer cells. Sabatier et al. [<xref ref-type="bibr" rid="CR22">22</xref>] investigated the <italic>PDL1</italic> level in 5, 454 breast cancers using DNA microarray and demonstrated that higher <italic>PDL1</italic> expression was associated with better metastasis-free survival and OSS and better response to chemotherapy. Additionally, Darb-Esfahani et al. [<xref ref-type="bibr" rid="CR27">27</xref>] detected the PD-1 and PD-L1 protein expression by IHC on TMA from 215 primary ovary cancers and described that PD-1 and PD-L1 expression in TCs were positive prognostic factors for progression-free survival and OS.</p><p>Now, it can only be speculated why the up-regulation of PD-1/PD-L1 axis are in some instances (such as in CRC in the present study) referred to a favorable clinical outcome. A positive impact of PD-L1 expression of TCs might be explained by a compensatory up-regulation of this marker in a microenvironment that threatens the tumor by an active immune response. An association between TCs-PD-L1 and a high TILs density would be an argument for this hypothesis, and has been well illustrated in breast cancer [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. However this hypothesis remains speculative. The positive prognostic impact of TILs-PD-1 may also base on regulatory and not yet completely elucidated mechanisms within the immune network in the tumor microenvironment. Therefore, regulatory and immune-suppressive T cells might be up-regulated during an enhanced anti-tumoral immune response.</p><p>Previous studies indicated that active immune microenvironment was observed in MSI/MMR-deficient tumors [<xref ref-type="bibr" rid="CR19">19</xref>], and these tumors are characterized by a more favorable prognosis compared to MSS/MMR-proficient tumors. MSI is typically diagnosed by the variable lengths of DNA microsatellites (mononucleotide and dinucleotide repeats), which is caused by epigenetic silencing or mutation of DNA MMR genes, leading to accumulated mutations at 10&#x02013;100 times the normal rate and promotes MSI carcinoma progression [<xref ref-type="bibr" rid="CR19">19</xref>]. In the MSI/MMR-deficient subset of CRC, the high accumulated mutation creates many tumor-specific neoantigens, typically 10&#x02013;50 times that of MSS/MMR-proficient subset [<xref ref-type="bibr" rid="CR29">29</xref>], which might be the reason for the high level of TILs and active Th1/CTL immune microenvironment in MSI/MMR-tumors observed in many previous studies [<xref ref-type="bibr" rid="CR19">19</xref>]. In the present study, subgroup analyses were carried out in FUSCC cohort and demonstrated that higher expressions of TILs-PD-1 and TCs-PD-L1 were associated with better prognosis in MMR-proficient subgroup while no correlation was found between TILs-PD-1/TCs-PD-L1 expression and prognosis. Surprisingly, TILs-PD-1 was even an independent factor for OS and DFS of CRC patients. The underline mechanisms remain unclear. IFN-&#x003b3;, mainly produced by activated infiltrating T cells, has been reported to be associated with a favorable prognosis [<xref ref-type="bibr" rid="CR30">30</xref>] and has been shown to promote the expression of PD-1 ligands in different cell types, which might mirror the co-overexpression of TILs-PD-1 and TCs-PD-L1 in MMR-proficient CRC. In the present study, among 356 eligible patients included in TCGA database, 250 patients have the data of IFN-&#x003b3; gene expression. Spearman test showed that both PD-1 and PDL-1 are highly directly correlated with IFN-&#x003b3; with <italic>r</italic>&#x02009;=&#x02009;0.7285 (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001, 95&#x000a0;% CI: 0.6624&#x02013;0.7833) and <italic>r</italic>&#x02009;=&#x02009;0.7475 (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001, 95&#x000a0;% CI: 0.6853&#x02013;0.7990), which supported the above hypothesis (Additional file <xref rid="MOESM3" ref-type="media">3</xref>: Figure S1). On the other hand, the intestinal immune system is shaped by a continuous interaction with commensal microbiota [<xref ref-type="bibr" rid="CR31">31</xref>]. Possibly, as a consequence of this specific microenvironment, CRC infiltration by immunocompetent cells is associated with paradoxically peculiar features [<xref ref-type="bibr" rid="CR32">32</xref>]. Indeed, previous studies [<xref ref-type="bibr" rid="CR33">33</xref>] demonstrated that, in contrast to a wide range of human cancers, CRC infiltration by FOXP3+ regulatory T cells, is associated with an improved prognosis. Furthermore, it has also been observed that CRC infiltration by myeloid cells is also associated with a favorable prognosis [<xref ref-type="bibr" rid="CR34">34</xref>].</p><p>To our knowledge, the present study is the first study based on East Asia patients concerning PD-1 and PD-L1 analyses, which combines TCGA database and center-based cohort to comprehensively and specifically investigate TILs-PD-1 and TCs-PD-L1 and their clinical relevance in CRC. However, our study has several limitations. First, the insufficient data on recurrence in CRC patients from in TCGA database limited the analyses on the impact of PD-1/PD-L1 expression for DFS. And the TCGA database does not include information regarding the pathological grading, nervous invasion and administration of chemotherapy and all these factors may affect the multivariate analysis of TCGA data. Secondly, although we have analyzed a large cohort, the present study is a retrospective analysis and there is a potential for selection bias. A relatively small sample of the MMR-deficient subgroup may result in lack of power for the Cox regression analysis and some of potential correlation between TILs-PD-1/TCs-PD-L1 expression and clinical outcome may fail to manifest. Thirdly, it is difficult to compare the results from our study with previous studies due to different antibodies and variant methodologies used to evaluate TILs-PD-1/TCs-PD-L1 expression.</p></sec><sec id="Sec15"><title>Conclusion</title><p>In conclusion, higher expression of PD-1 and PD-L1 is associated with better prognosis of CRC patients in TCGA and FUSCC cohort. TILs-PD-1 expression was an independent prognostic factor for OS and DFS of CRC patients, especially for MMR-proficient tumors. Future investigations should focus on PD-1/PD-L1 expression on TILs, instead of only on TCs.</p></sec></body><back><app-group><app id="App1"><sec id="Sec16"><title>Additional files</title><p><media position="anchor" xlink:href="12943_2016_539_MOESM1_ESM.docx" id="MOESM1"><label>Additional file 1: Table S1.</label><caption><p>Univariate and multivariate Cox proportional hazards analysis of OS and DFS for patients with CRC in MMR-proficient subgroup of the FUSCC cohort. (DOCX 18&#x000a0;kb)</p></caption></media><media position="anchor" xlink:href="12943_2016_539_MOESM2_ESM.docx" id="MOESM2"><label>Additional file 2: Table S2.</label><caption><p>Univariate and multivariate Cox proportional hazards analysis of OS and DFS for patients with CRC in MMR-deficient subgroup of the FUSCC cohort. (DOCX 17&#x000a0;kb)</p></caption></media><media position="anchor" xlink:href="12943_2016_539_MOESM3_ESM.tif" id="MOESM3"><label>Additional file 3: Figure S1.</label><caption><p>Correlation of PD-1/PD-L1 and IFN-&#x003b3; in TCGA database. In TCGA cohort, 250 patients have the data of IFN-&#x003b3; gene expression. Spearman test was used to determine the correlation of PD-1/PD-L1 and IFN-&#x003b3;. (a) The expression of PD-1 is directly correlated with IFN-&#x003b3; (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001, <italic>r</italic>&#x02009;=&#x02009;0.7285, 95&#x000a0;% CI: 0.6624&#x02013;0.7833). (b) The expression of PD-L1 is directly correlated with IFN-&#x003b3; (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001, <italic>r</italic>&#x02009;=&#x02009;0.7475, 95&#x000a0;% CI: 0.6853&#x02013;0.7990). (TIF 1066&#x000a0;kb)</p></caption></media></p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>CRC</term><def><p>Colorectal cancer</p></def></def-item><def-item><term>FUSCC</term><def><p>Fudan University Shanghai Cancer Center</p></def></def-item><def-item><term>IRS</term><def><p>Immunoreactivity score</p></def></def-item><def-item><term>MMR</term><def><p>Mismatch repair</p></def></def-item><def-item><term>MS</term><def><p>Microsatellite</p></def></def-item><def-item><term>SRCC</term><def><p>Signet ring colorectal cancer</p></def></def-item><def-item><term>TCGA</term><def><p>The cancer genome atlas</p></def></def-item><def-item><term>TCs</term><def><p>Tumor cells</p></def></def-item><def-item><term>TILs</term><def><p>Tumor infiltrating cells</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>The authors acknowledge the efforts of The Cancer Genome Atlas in the creation of the database. The interpretation and reporting of these data are the sole responsibility of the authors.</p><sec id="FPar1"><title>Funding</title><p>This work was supported by the National Natural Science Foundation of China (Grant No. 81372646, 81101586) and National Key Basic Research Program of China (2014CBA02002).</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p>The datasets supporting the conclusions of this article are included within the article and its additional files.</p></sec><sec id="FPar3"><title>Authors&#x02019; contributions</title><p>XL and QL conceived this study. GC and YX improved the study design and contributed to the interpretation of results. YL and WD performed IHC staining. LL performed data processing and statistical analysis. QL and YL wrote the manuscript. SC revised the manuscript and approved the final version. All authors read and approved the final manuscript.</p></sec><sec id="FPar4"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar5"><title>Consent for publication</title><p>Not applicable.</p></sec><sec id="FPar6"><title>Ethics approval and consent to participate</title><p>TMA was constructed with materials collected from Tissue Bank of FUSCC and this institution is allowed to perform translational research with the approval of the Ethical Committee and Institutional Review Board of FUSCC in compliance with ethical standards and patient confidentiality.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torre</surname><given-names>LA</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Lortet-Tieulent</surname><given-names>J</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Global cancer statistics, 2012</article-title><source>CA Cancer J Clin</source><year>2015</year><volume>65</volume><fpage>87</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.3322/caac.21262</pub-id><?supplied-pmid 25651787?><pub-id pub-id-type="pmid">25651787</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Topalian</surname><given-names>SL</given-names></name><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>Brahmer</surname><given-names>JR</given-names></name><name><surname>Gettinger</surname><given-names>SN</given-names></name><name><surname>Smith</surname><given-names>DC</given-names></name><name><surname>Mcdermott</surname><given-names>DF</given-names></name><name><surname>Powderly</surname><given-names>JD</given-names></name></person-group><article-title>Safety, activity, and immune correlates of anti&#x02013;PD-1 antibody in cancer</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><fpage>2443</fpage><lpage>2454</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1200690</pub-id><?supplied-pmid 22658127?><pub-id pub-id-type="pmid">22658127</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Freeman</surname><given-names>GJ</given-names></name></person-group><article-title>The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy</article-title><source>Cancer Discov</source><year>2015</year><volume>5</volume><fpage>16</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-14-1397</pub-id><?supplied-pmid 25583798?><pub-id pub-id-type="pmid">25583798</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Costes</surname><given-names>A</given-names></name><name><surname>Sanchez-Cabo</surname><given-names>F</given-names></name><name><surname>Kirilovsky</surname><given-names>A</given-names></name><name><surname>Mlecnik</surname><given-names>B</given-names></name><name><surname>Lagorce-Pag&#x000e9;s</surname><given-names>C</given-names></name></person-group><article-title>Type, density, and location of immune cells within human colorectal tumors predict clinical outcome</article-title><source>Science</source><year>2006</year><volume>313</volume><fpage>1960</fpage><lpage>1964</lpage><pub-id pub-id-type="doi">10.1126/science.1129139</pub-id><?supplied-pmid 17008531?><pub-id pub-id-type="pmid">17008531</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name></person-group><article-title>Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity</article-title><source>Nat Rev Immunol</source><year>2004</year><volume>4</volume><fpage>336</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1038/nri1349</pub-id><?supplied-pmid 15122199?><pub-id pub-id-type="pmid">15122199</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Latchman</surname><given-names>Y</given-names></name><name><surname>Wood</surname><given-names>CR</given-names></name><name><surname>Chernova</surname><given-names>T</given-names></name><name><surname>Chaudhary</surname><given-names>D</given-names></name><name><surname>Borde</surname><given-names>M</given-names></name><name><surname>Chernova</surname><given-names>I</given-names></name><name><surname>Iwai</surname><given-names>Y</given-names></name><name><surname>Long</surname><given-names>AJ</given-names></name><name><surname>Brown</surname><given-names>JA</given-names></name><name><surname>Nunes</surname><given-names>R</given-names></name><etal/></person-group><article-title>PD-L2 is a second ligand for PD-1 and inhibits T cell activation</article-title><source>Nat Immuol</source><year>2001</year><volume>2</volume><fpage>261</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1038/85330</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keir</surname><given-names>ME</given-names></name><name><surname>Liang</surname><given-names>SC</given-names></name><name><surname>Guleria</surname><given-names>I</given-names></name><name><surname>Latchman</surname><given-names>YE</given-names></name><name><surname>Qipo</surname><given-names>A</given-names></name><name><surname>Albacker</surname><given-names>LA</given-names></name><name><surname>Koulmanda</surname><given-names>M</given-names></name><name><surname>Freeman</surname><given-names>GJ</given-names></name><name><surname>Sayegh</surname><given-names>MH</given-names></name><name><surname>Sharpe</surname><given-names>AH</given-names></name></person-group><article-title>Tissue expression of PD-L1 mediates peripheral T cell tolerance</article-title><source>J Exp Med</source><year>2006</year><volume>203</volume><fpage>883</fpage><lpage>895</lpage><pub-id pub-id-type="doi">10.1084/jem.20051776</pub-id><?supplied-pmid 16606670?><pub-id pub-id-type="pmid">16606670</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keir</surname><given-names>ME</given-names></name><name><surname>Butte</surname><given-names>MJ</given-names></name><name><surname>Freeman</surname><given-names>GJ</given-names></name><name><surname>Sharpe</surname><given-names>AH</given-names></name></person-group><article-title>PD-1 and its ligands in tolerance and immunity</article-title><source>Annu Rev Immunol</source><year>2008</year><volume>26</volume><fpage>677</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.26.021607.090331</pub-id><?supplied-pmid 18173375?><pub-id pub-id-type="pmid">18173375</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okazaki</surname><given-names>T</given-names></name><name><surname>Honjo</surname><given-names>T</given-names></name></person-group><article-title>The PD-1-PD-L pathway in immunological tolerance</article-title><source>Trends Immunol</source><year>2006</year><volume>27</volume><fpage>195</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1016/j.it.2006.02.001</pub-id><?supplied-pmid 16500147?><pub-id pub-id-type="pmid">16500147</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herbst</surname><given-names>RS</given-names></name><name><surname>Soria</surname><given-names>JC</given-names></name><name><surname>Kowanetz</surname><given-names>M</given-names></name><name><surname>Fine</surname><given-names>GD</given-names></name><name><surname>Hamid</surname><given-names>O</given-names></name><name><surname>Gordon</surname><given-names>MS</given-names></name><name><surname>Sosman</surname><given-names>JA</given-names></name><name><surname>McDermott</surname><given-names>DF</given-names></name><name><surname>Powderly</surname><given-names>JD</given-names></name><name><surname>Gettinger</surname><given-names>SN</given-names></name><etal/></person-group><article-title>Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients</article-title><source>Nature</source><year>2014</year><volume>515</volume><fpage>563</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1038/nature14011</pub-id><?supplied-pmid 25428504?><pub-id pub-id-type="pmid">25428504</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Awad</surname><given-names>MM</given-names></name><name><surname>Hammerman</surname><given-names>PS</given-names></name></person-group><article-title>Durable responses with PD-1 inhibition in lung and kidney cancer and the ongoing search for predictive biomarkers</article-title><source>J Clin Oncol</source><year>2015</year><volume>33</volume><fpage>1993</fpage><lpage>1994</lpage><pub-id pub-id-type="doi">10.1200/JCO.2015.61.4172</pub-id><?supplied-pmid 25918290?><pub-id pub-id-type="pmid">25918290</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powles</surname><given-names>T</given-names></name><name><surname>Eder</surname><given-names>JP</given-names></name><name><surname>Fine</surname><given-names>GD</given-names></name><name><surname>Braiteh</surname><given-names>FS</given-names></name><name><surname>Loriot</surname><given-names>Y</given-names></name><name><surname>Cruz</surname><given-names>C</given-names></name><name><surname>Bellmunt</surname><given-names>J</given-names></name><name><surname>Burris</surname><given-names>HA</given-names></name><name><surname>Petrylak</surname><given-names>DP</given-names></name><name><surname>Teng</surname><given-names>SL</given-names></name><etal/></person-group><article-title>MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer</article-title><source>Nature</source><year>2014</year><volume>515</volume><fpage>558</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1038/nature13904</pub-id><?supplied-pmid 25428503?><pub-id pub-id-type="pmid">25428503</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>YZ</given-names></name><name><surname>Yu</surname><given-names>KD</given-names></name><name><surname>Zuo</surname><given-names>WJ</given-names></name><name><surname>Peng</surname><given-names>WT</given-names></name><name><surname>Shao</surname><given-names>ZM</given-names></name></person-group><article-title>GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival</article-title><source>Cancer</source><year>2014</year><volume>120</volume><fpage>1329</fpage><lpage>1337</lpage><pub-id pub-id-type="doi">10.1002/cncr.28566</pub-id><?supplied-pmid 24477928?><pub-id pub-id-type="pmid">24477928</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauter</surname><given-names>G</given-names></name><name><surname>Simon</surname><given-names>R</given-names></name><name><surname>Hillan</surname><given-names>K</given-names></name></person-group><article-title>Tissue microarrays in drug discovery</article-title><source>Nat Rev Drug Discov</source><year>2003</year><volume>2</volume><fpage>962</fpage><lpage>972</lpage><pub-id pub-id-type="doi">10.1038/nrd1254</pub-id><?supplied-pmid 14654795?><pub-id pub-id-type="pmid">14654795</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas N</collab></person-group><article-title>Comprehensive molecular characterization of human colon and rectal cancer</article-title><source>Nature</source><year>2012</year><volume>487</volume><fpage>330</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1038/nature11252</pub-id><pub-id pub-id-type="pmid">22810696</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lugli</surname><given-names>A</given-names></name><name><surname>Zlobec</surname><given-names>I</given-names></name><name><surname>Baker</surname><given-names>K</given-names></name><name><surname>Minoo</surname><given-names>P</given-names></name><name><surname>Tornillo</surname><given-names>L</given-names></name><name><surname>Terracciano</surname><given-names>L</given-names></name><name><surname>Jass</surname><given-names>JR</given-names></name></person-group><article-title>Prognostic significance of mucins in colorectal cancer with different DNA mismatch-repair status</article-title><source>J Clin Pathol</source><year>2007</year><volume>60</volume><fpage>534</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1136/jcp.2006.039552</pub-id><?supplied-pmid 16816167?><pub-id pub-id-type="pmid">16816167</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>K</given-names></name><name><surname>Zlobec</surname><given-names>I</given-names></name><name><surname>Tornillo</surname><given-names>L</given-names></name><name><surname>Terracciano</surname><given-names>L</given-names></name><name><surname>Jass</surname><given-names>JR</given-names></name><name><surname>Lugli</surname><given-names>A</given-names></name></person-group><article-title>Differential significance of tumour infiltrating lymphocytes in sporadic mismatch repair deficient versus proficient colorectal cancers: a potential role for dysregulation of the transforming growth factor-beta pathway</article-title><source>Eur J Cancer</source><year>2007</year><volume>43</volume><fpage>624</fpage><lpage>631</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2006.11.012</pub-id><?supplied-pmid 17223543?><pub-id pub-id-type="pmid">17223543</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camp</surname><given-names>RL</given-names></name><name><surname>Dolled-Filhart</surname><given-names>M</given-names></name><name><surname>Rimm</surname><given-names>DL</given-names></name></person-group><article-title>X-tile: a New Bio-informatics tool for biomarker assessment and outcome-based Cut-point optimization</article-title><source>Clin Cancer Res</source><year>2004</year><volume>10</volume><fpage>7252</fpage><lpage>7259</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-0713</pub-id><?supplied-pmid 15534099?><pub-id pub-id-type="pmid">15534099</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smyrk</surname><given-names>TC</given-names></name><name><surname>Watson</surname><given-names>P</given-names></name><name><surname>Kaul</surname><given-names>K</given-names></name><name><surname>Lynch</surname><given-names>HT</given-names></name></person-group><article-title>Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma</article-title><source>Cancer</source><year>2001</year><volume>91</volume><fpage>2417</fpage><lpage>2422</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(20010615)91:12&#x0003c;2417::AID-CNCR1276&#x0003e;3.0.CO;2-U</pub-id><?supplied-pmid 11413533?><pub-id pub-id-type="pmid">11413533</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>SP</given-names></name><name><surname>Kurzrock</surname><given-names>R</given-names></name></person-group><article-title>PD-L1 expression as a predictive biomarker in cancer immunotherapy</article-title><source>Mol Cancer Ther</source><year>2015</year><volume>14</volume><fpage>847</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-14-0983</pub-id><?supplied-pmid 25695955?><pub-id pub-id-type="pmid">25695955</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choueiri</surname><given-names>TK</given-names></name><name><surname>Fay</surname><given-names>AP</given-names></name><name><surname>Gray</surname><given-names>KP</given-names></name><name><surname>Callea</surname><given-names>M</given-names></name><name><surname>Ho</surname><given-names>TH</given-names></name><name><surname>Albiges</surname><given-names>L</given-names></name><name><surname>Bellmunt</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Carvo</surname><given-names>I</given-names></name><name><surname>Lampron</surname><given-names>M</given-names></name><etal/></person-group><article-title>PD-L1 expression in nonclear-cell renal cell carcinoma</article-title><source>Ann Oncol</source><year>2014</year><volume>25</volume><fpage>2178</fpage><lpage>2184</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdu445</pub-id><?supplied-pmid 25193987?><pub-id pub-id-type="pmid">25193987</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schalper</surname><given-names>KA</given-names></name><name><surname>Velcheti</surname><given-names>V</given-names></name><name><surname>Carvajal</surname><given-names>D</given-names></name><name><surname>Wimberly</surname><given-names>H</given-names></name><name><surname>Brown</surname><given-names>J</given-names></name><name><surname>Pusztai</surname><given-names>L</given-names></name><name><surname>Rimm</surname><given-names>DL</given-names></name></person-group><article-title>In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas</article-title><source>Clin Cancer Res</source><year>2014</year><volume>20</volume><fpage>2773</fpage><lpage>2782</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-2702</pub-id><?supplied-pmid 24647569?><pub-id pub-id-type="pmid">24647569</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>CY</given-names></name><name><surname>Lin</surname><given-names>MW</given-names></name><name><surname>Chang</surname><given-names>YL</given-names></name><name><surname>Wu</surname><given-names>CT</given-names></name><name><surname>Yang</surname><given-names>PC</given-names></name></person-group><article-title>Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma</article-title><source>Eur J Cancer</source><year>2016</year><volume>57</volume><fpage>91</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2015.12.033</pub-id><?supplied-pmid 26901614?><pub-id pub-id-type="pmid">26901614</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Kang</surname><given-names>S</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Peng</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>W</given-names></name></person-group><article-title>Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) expression in epithelial-originated cancer: a meta-analysis</article-title><source>Medicine (Baltimore)</source><year>2015</year><volume>94</volume><fpage>e515</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000000515</pub-id><pub-id pub-id-type="pmid">25674748</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Droeser</surname><given-names>RA</given-names></name><name><surname>Hirt</surname><given-names>C</given-names></name><name><surname>Viehl</surname><given-names>CT</given-names></name><name><surname>Frey</surname><given-names>DM</given-names></name><name><surname>Nebiker</surname><given-names>C</given-names></name><name><surname>Huber</surname><given-names>X</given-names></name><name><surname>Zlobec</surname><given-names>I</given-names></name><name><surname>Eppenberger-Castori</surname><given-names>S</given-names></name><name><surname>Tzankov</surname><given-names>A</given-names></name><name><surname>Rosso</surname><given-names>R</given-names></name><etal/></person-group><article-title>Clinical impact of programmed cell death ligand 1 expression in colorectal cancer</article-title><source>Eur J Cancer</source><year>2013</year><volume>49</volume><fpage>2233</fpage><lpage>2242</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2013.02.015</pub-id><?supplied-pmid 23478000?><pub-id pub-id-type="pmid">23478000</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lussier</surname><given-names>DM</given-names></name><name><surname>Johnson</surname><given-names>JL</given-names></name><name><surname>Hingorani</surname><given-names>P</given-names></name><name><surname>Blattman</surname><given-names>JN</given-names></name></person-group><article-title>Combination immunotherapy with alpha-CTLA-4 and alpha-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma</article-title><source>J Immunother Cancer</source><year>2015</year><volume>3</volume><fpage>21</fpage><pub-id pub-id-type="doi">10.1186/s40425-015-0067-z</pub-id><?supplied-pmid 25992292?><pub-id pub-id-type="pmid">25992292</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darb-Esfahani</surname><given-names>S</given-names></name><name><surname>Kunze</surname><given-names>CA</given-names></name><name><surname>Kulbe</surname><given-names>H</given-names></name><name><surname>Sehouli</surname><given-names>J</given-names></name><name><surname>Wienert</surname><given-names>S</given-names></name><name><surname>Lindner</surname><given-names>J</given-names></name><name><surname>Bockmayr</surname><given-names>M</given-names></name><name><surname>Dietel</surname><given-names>M</given-names></name><name><surname>Denkert</surname><given-names>C</given-names></name><name><surname>Braicu</surname><given-names>I</given-names></name><name><surname>J&#x000d6;hrens</surname><given-names>K</given-names></name></person-group><article-title>Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>1486</fpage><lpage>1499</lpage><?supplied-pmid 26625204?><pub-id pub-id-type="pmid">26625204</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabatier</surname><given-names>R</given-names></name><name><surname>Finetti</surname><given-names>P</given-names></name><name><surname>Mamessier</surname><given-names>E</given-names></name><name><surname>Adelaide</surname><given-names>J</given-names></name><name><surname>Chaffanet</surname><given-names>M</given-names></name><name><surname>Ali</surname><given-names>H</given-names></name><name><surname>Viens</surname><given-names>P</given-names></name><name><surname>Caldas</surname><given-names>C</given-names></name><name><surname>Brinbaum</surname><given-names>D</given-names></name><name><surname>Bertucci</surname><given-names>F</given-names></name></person-group><article-title>Prognostic and predictive value of PDL1 expression in breast cancer</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>5449</fpage><lpage>5464</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.3216</pub-id><?supplied-pmid 25669979?><pub-id pub-id-type="pmid">25669979</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llosa</surname><given-names>NJ</given-names></name><name><surname>Cruise</surname><given-names>M</given-names></name><name><surname>Tam</surname><given-names>A</given-names></name><name><surname>Wicks</surname><given-names>EC</given-names></name><name><surname>Hechenbleikner</surname><given-names>EM</given-names></name><name><surname>Taube</surname><given-names>JM</given-names></name><name><surname>Blosser</surname><given-names>RL</given-names></name><name><surname>Fan</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Luber</surname><given-names>BS</given-names></name><etal/></person-group><article-title>The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints</article-title><source>Cancer Discov</source><year>2015</year><volume>5</volume><fpage>43</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-14-0863</pub-id><?supplied-pmid 25358689?><pub-id pub-id-type="pmid">25358689</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pag&#x000e8;s</surname><given-names>F</given-names></name><name><surname>Berger</surname><given-names>A</given-names></name><name><surname>Camus</surname><given-names>M</given-names></name><name><surname>Sanchez-Cabo</surname><given-names>F</given-names></name><name><surname>Costes</surname><given-names>A</given-names></name><name><surname>Molidor</surname><given-names>R</given-names></name><name><surname>Mlecnik</surname><given-names>B</given-names></name><name><surname>Kirilovsky</surname><given-names>A</given-names></name><name><surname>Nilsson</surname><given-names>M</given-names></name><name><surname>Damotte</surname><given-names>D</given-names></name><etal/></person-group><article-title>Effector memory T cells, early metastasis, and survival in colorectal cancer</article-title><source>N Engl J Med</source><year>2005</year><volume>353</volume><fpage>2654</fpage><lpage>2666</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa051424</pub-id><?supplied-pmid 16371631?><pub-id pub-id-type="pmid">16371631</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kau</surname><given-names>AL</given-names></name><name><surname>Ahern</surname><given-names>PP</given-names></name><name><surname>Griffin</surname><given-names>NW</given-names></name><name><surname>Goodman</surname><given-names>AL</given-names></name><name><surname>Gordon</surname><given-names>JI</given-names></name></person-group><article-title>Human nutrition, the gut microbiome and the immune system</article-title><source>Nature</source><year>2011</year><volume>474</volume><fpage>327</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1038/nature10213</pub-id><?supplied-pmid 21677749?><pub-id pub-id-type="pmid">21677749</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ladoire</surname><given-names>S</given-names></name><name><surname>Martin</surname><given-names>F</given-names></name><name><surname>Ghiringhelli</surname><given-names>F</given-names></name></person-group><article-title>Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas- the paradox of colorectal cancer</article-title><source>Cancer Immunol Immunother</source><year>2011</year><volume>60</volume><fpage>909</fpage><lpage>918</lpage><pub-id pub-id-type="doi">10.1007/s00262-011-1046-y</pub-id><?supplied-pmid 21644034?><pub-id pub-id-type="pmid">21644034</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salama</surname><given-names>P</given-names></name><name><surname>Phillips</surname><given-names>M</given-names></name><name><surname>Grieu</surname><given-names>F</given-names></name><name><surname>Morris</surname><given-names>M</given-names></name><name><surname>Zeps</surname><given-names>N</given-names></name><name><surname>Joseph</surname><given-names>D</given-names></name><name><surname>Platell</surname><given-names>C</given-names></name><name><surname>Iacopetta</surname><given-names>B</given-names></name></person-group><article-title>Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>186</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.18.7229</pub-id><?supplied-pmid 19064967?><pub-id pub-id-type="pmid">19064967</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sconocchia</surname><given-names>G</given-names></name><name><surname>Zlobec</surname><given-names>I</given-names></name><name><surname>Lugli</surname><given-names>A</given-names></name><name><surname>Calabrese</surname><given-names>D</given-names></name><name><surname>Iezzi</surname><given-names>G</given-names></name><name><surname>Karamitopoulou</surname><given-names>E</given-names></name><name><surname>Patsouris</surname><given-names>ES</given-names></name><name><surname>Peros</surname><given-names>G</given-names></name><name><surname>Horcic</surname><given-names>M</given-names></name><name><surname>Tornillo</surname><given-names>L</given-names></name><etal/></person-group><article-title>Tumor infiltration by FcgammaRIII (CD16)&#x02009;+&#x02009;myeloid cells is associated with improved survival in patients with colorectal carcinoma</article-title><source>Int J Cancer</source><year>2011</year><volume>128</volume><fpage>2663</fpage><lpage>2672</lpage><pub-id pub-id-type="doi">10.1002/ijc.25609</pub-id><?supplied-pmid 20715106?><pub-id pub-id-type="pmid">20715106</pub-id></element-citation></ref></ref-list></back></article>